DE69233012D1 - Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i - Google Patents

Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i

Info

Publication number
DE69233012D1
DE69233012D1 DE69233012T DE69233012T DE69233012D1 DE 69233012 D1 DE69233012 D1 DE 69233012D1 DE 69233012 T DE69233012 T DE 69233012T DE 69233012 T DE69233012 T DE 69233012T DE 69233012 D1 DE69233012 D1 DE 69233012D1
Authority
DE
Germany
Prior art keywords
type
epidermidis
serotypes
staphylococcus epidermidis
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233012T
Other languages
English (en)
Other versions
DE69233012T2 (de
Inventor
Ibrahim Fattom
Craig Wright
W Karakawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fattom Ali Ibrahim Rockville Md Us
Wright Dcraig Gaithersburg Md Us
Vaxart Inc
Original Assignee
UNIVAX BIOLOGICS Inc ROCKVILLE
Univax Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNIVAX BIOLOGICS Inc ROCKVILLE, Univax Biologics Inc filed Critical UNIVAX BIOLOGICS Inc ROCKVILLE
Application granted granted Critical
Publication of DE69233012D1 publication Critical patent/DE69233012D1/de
Publication of DE69233012T2 publication Critical patent/DE69233012T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69233012T 1991-11-22 1992-11-20 Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i Expired - Lifetime DE69233012T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79625291A 1991-11-22 1991-11-22
PCT/US1992/009784 WO1993009811A1 (en) 1991-11-22 1992-11-20 TYPE I AND TYPE II SURFACE ANTIGENS ASSOCIATED WITH $i(STAPHYLOCOCCUS EPIDERMIDIS)

Publications (2)

Publication Number Publication Date
DE69233012D1 true DE69233012D1 (de) 2003-05-22
DE69233012T2 DE69233012T2 (de) 2003-11-06

Family

ID=25167715

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69233012T Expired - Lifetime DE69233012T2 (de) 1991-11-22 1992-11-20 Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i

Country Status (12)

Country Link
US (2) US5866140A (de)
EP (1) EP0648127B1 (de)
JP (2) JP4087896B2 (de)
AT (1) ATE237351T1 (de)
AU (1) AU681573B2 (de)
CA (1) CA2123811C (de)
DE (1) DE69233012T2 (de)
DK (1) DK0648127T3 (de)
ES (1) ES2198405T3 (de)
FI (1) FI111336B (de)
NO (1) NO319013B1 (de)
WO (1) WO1993009811A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US7279162B1 (en) 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
US5955074A (en) * 1990-10-22 1999-09-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Directed human immune globulin for the prevention and treatment of staphylococcal infections
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
JP4160633B2 (ja) * 1994-09-21 2008-10-01 ヘンリー エム.ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン 共通のブドウ球菌抗原と広範に反応するオプソニン作用性抗体
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
WO2000012132A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
EP1121135B1 (de) * 1998-09-14 2009-01-28 Nabi Biopharmaceuticals Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
WO2001034809A2 (en) * 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
US6703492B1 (en) 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
CA2501077C (en) 2002-11-12 2016-06-21 Gerald B. Pier Polysaccharide vaccine for staphylococcal infections
WO2004043407A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
EP2305294B1 (de) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
EP2298341A3 (de) 2004-10-21 2011-07-13 Wyeth LLC Immunogene zusammensetzungen von staphylococcus epidermidis polypeptide und polynucleotide antigenen
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US20060153857A1 (en) * 2005-01-10 2006-07-13 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
CA2611023A1 (en) 2005-06-13 2006-12-21 Nabi Biopharmaceuticals Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
NZ574057A (en) 2006-06-12 2012-01-12 Glaxosmithkline Biolog Sa Staphylococcal antigen composition comprising an isolated S. aureus type 5 antigen; an isolated S. aureus type 8 antigen; an isolated S. aureus 336 antigen; an isolated S. aureus alpha-toxin antigen; and an isolated Staphylococcal leukocidin antigen
US7754225B2 (en) * 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection
AU2008280799B2 (en) * 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
RU2532911C2 (ru) 2008-07-21 2014-11-20 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам
JP2012530785A (ja) 2009-06-22 2012-12-06 ワイス・エルエルシー 組成物および黄色ブドウ球菌(Staphylococcusaureus)血清型5および8莢膜多糖コンジュゲート免疫原性組成物を調製するための方法
WO2010151544A1 (en) 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
JP5914344B2 (ja) 2009-10-30 2016-05-11 ノバルティス アーゲー Staphylococcusaureus5型および8型の莢膜糖の精製
WO2012075428A1 (en) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition for immunization against streptococcus pneumoniae
CN113730648B (zh) * 2021-09-06 2022-11-01 温州瑞司特生物科技有限公司 结合表皮葡萄球菌的水凝胶及其在治疗创面中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5452794A (en) * 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
FR2619122B1 (fr) * 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens

Also Published As

Publication number Publication date
JP4087896B2 (ja) 2008-05-21
FI942359A0 (fi) 1994-05-20
EP0648127B1 (de) 2003-04-16
NO941877D0 (no) 1994-05-19
ES2198405T3 (es) 2004-02-01
NO319013B1 (no) 2005-06-06
AU3074792A (en) 1993-06-15
EP0648127A1 (de) 1995-04-19
CA2123811C (en) 2005-07-05
FI942359A (fi) 1994-05-20
CA2123811A1 (en) 1993-05-27
DE69233012T2 (de) 2003-11-06
EP0648127A4 (de) 1995-06-14
US5866140A (en) 1999-02-02
FI111336B (fi) 2003-07-15
ATE237351T1 (de) 2003-05-15
AU681573B2 (en) 1997-09-04
NO941877L (no) 1994-06-16
US5961975A (en) 1999-10-05
JPH07508498A (ja) 1995-09-21
DK0648127T3 (da) 2003-05-19
JP2004155789A (ja) 2004-06-03
JP4353789B2 (ja) 2009-10-28
WO1993009811A1 (en) 1993-05-27

Similar Documents

Publication Publication Date Title
DE69233012D1 (de) Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
EP0077734A3 (de) Herstellung von monoklonalen Antikörpern gegen bakterielle Adhesine
PT1162997E (pt) Antigenio de staphylococcus e a respectiva vacina
ATE188708T1 (de) Antikörperderivate
DK450183A (da) Humane monoklone antistoffer mod et bakterietoksin samt disses fremstilling, kontinuerlige cellelinier, som producerer antitoksin-antistoffer, samt antistoffernes anvendelser
ATE7761T1 (de) Impfstoff und herstellungsverfahren.
EP0041897A3 (en) Polysaccharide antigen from streptococcus and vaccine containing the same
MX9203629A (es) Composiciones de anticuerpos monoclonales para el tratamiento profilactico o terapeutico de infecciones bacterianas debidas a estreptococos del grupo b.
SE9000333D0 (sv) Monoklonal antikropp
PT1042492E (pt) Anticorpos monoclonais humanizados que protegem contra doença induzida pela toxina shiga
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
DE3686158D1 (de) Impfstoff gegen mastitis.
YU22693A (sh) Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije
EP0327648A4 (de) Menschlicher monoklonaler antikörper und arzneimittel zur prophylaxe und behandlung von infektiösen krankheiten.
SE7712244L (sv) Forfarande for framstellning av preparationer av avdodade bakterier
DE69025629D1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids-verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
DE69232140D1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
ZA916313B (en) New use of a monoclonal antibody
ATE110786T1 (de) Monoklonaler antikörper gegen exotoxin a von pseudomonas aeruginosa.
DE3381985D1 (de) Verwendung von peptiden.
DE68924963D1 (de) Zusammensetzungen und Methoden zur Behandlung und Vorbeugung von Gram-Negativen-Infektionen.
IT210111Z2 (it) Rete ombreggiante e rinfrescante per colture delicate.
SU1565021A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus - продуцент моноклональных антител к вирусу ящура 0-01618
RU92016461A (ru) Культура, линия клеток, моноклональные антитела, способ получения моноклональных антител, способ лечения, способ диагностики
BG51639A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody towards antigenous determinant of strain " hantaan " of the virus of haemorrhagic fever with nephritic syndrome

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NABI BIOPHARMACUTICALS, ROCKVILLE, MD, US

Owner name: FATTOM, ALI IBRAHIM, ROCKVILLE, MD., US

Owner name: WRIGHT, D.CRAIG, GAITHERSBURG, MD., US

8364 No opposition during term of opposition